Saskia de Wildt and colleagues, theme Renal disorders, obtained an EU Horizon 2020 grant of € 123.000 for a new research infrastructure that will facilitate the future development of better paediatric medicines.Children and young people represent 20 % of the European population. When we refer to this group of people as patients, it’s essential to consider that they are different from the adult patients. Their metabolism is different, because they are in continuous development and also they can suffer diseases that sometimes might be limited to the paediatric setting.Taking into consideration these specificities, the need of treatments addressed only for children is a public priority. Nowadays around 50% of the medicines that are prescribed to paediatric patients have not been tested specially for them. For this reason, it is essential to promote and increase paediatric research.
The translation between bench to the bedside requires the involvement of different expert research groups in drug early discovery, biomarkers, formulation, pharmacology, etc. that already collaborate in Europe within the already existing research infrastructures. But the problem is that they do not are specifically dedicated to research in children.The time needed for the development of new medicines is also an important concern. It is long, from the basic research (before the study of a potential treatment with humans) to the clinical research (when we study this potential treatment with patients). It can also take among 7-10 years from the screening of new molecules to the market of a new drug and the average of success rate is really low (1 over 10.000 molecules studied). For this reason, it's essential to join efforts and work in a collaborative way between the European experts groups that at this moment are working to develop paediatric medicines.
ID-EPTRI is a project funded by the European Commission that has as main objective to design the framework for the European Paediatric Translational Research Infrastructure (EPTRI). A research infrastructure is a set of facilities, resources and related services at disposal of the scientific community to conduct top-level research. EPTRI will be a new research infrastructure that will integrate the paediatric expertise of five different areas of pre-clinical research: early discovery and preclinical studies, biomarkers, pharmacology, formulation and underpinning paediatric studies. The main objective of ID-EPTRI is to facilitate the paediatric pre-clinical research while reducing the time of its translation to the clinical phase.
The project involves 26 partners from EU and non-EU countries including already existing research infrastructures, top-level universities, scientific and clinical centers of excellence in Europe. It is coordinated by Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF), a not-for-profit organization, founded in 2000 with the mission to perform research and provide scientific, economic and regulatory consultancy for innovation in the health sector at European level.
Saskia de Wildt, project leader, is member of the theme Renal disorders.
Related news items
The Postdoctoral Networking Tour in artificial intelligence2 July 2020
You are a postdoctoral researcher in the field of artificial intelligence? The Postdoc-NeT-AI offers you the opportunity to participate in one week of on-site visits to leading German universities, research institutes and companies. Apply now to this year's tour until 16 August 2020.read more
Register for Phd courses via gROW What does this mean for you?2 July 2020
From now on you can arrange everything related to the general RU PhD courses via gROW. Because of this there will be some changes in the registration! What does this mean for you?read more
Experts on metabolic diseases still an unknown major problem...1 July 2020
Six Dutch UMCs and a patient association contribute to treating and solving this major, often unknown, problem. Timely detection of metabolic diseases is vital. Therefore, Radboudumc is also part of the consortium “United for Metabolic Diseases”.read more
Radboud Pluim for Lionne Ekers ambassador for the RIMLS institute30 June 2020
Lionne Ekers received the Radboudpluim for her special merits for the Radboudumc. She is a born ambassador for our Institute.read more
Stefan Listl member Lancet Commission on Oral Health29 June 2020
In recognition of the global public health importance, woeful neglect of oral diseases, and the need for a broader understanding and commitment to global oral health within medicine and global health agendas, The Lancet recently established a Commission on Oral Health.read more
Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection29 June 2020
In a review in Cell Mihai Netea, Frank van de Veerdonk, Reinout van Crevel and Jorge Dominguez Andres propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2.read more